FLHASc评分在急诊科咯血患者风险分层中的验证与实施
该研究基于POPEIHE多中心前瞻性队列(NCT06067997),纳入9家意大利急诊科连续就诊的546例成人咯血患者,主要终点为院内死亡、需通气支持、ICU入住、输血或有创止血操作的复合终点。原始FLHASc区分度中等(AUC 0.71,95%CI 0.65-0.76),校准欠佳;新推导的FLHASc2在推导队列AUC 0.79(95%CI 0.73-0.87)、验证队列AUC 0.81(95%CI 0.73-0.88),Brier评分均<0.10。简化版sFLHASc2每变量计1分,准确度相当(AUC 0.80,95%CI 0.72-0.87),识别47.8%患者为低危(事件率2.7%);联合胸片阴性时该亚组事件率降至0.87%,阴性预测值99.1%(95%CI 96.5-100%)。作者结论认为sFLHASc2联合胸片可能使近半数病例安全离院,但需前瞻性管理试验确认。
要点
- sFLHASc2每变量计1分,将47.8%的急诊咯血患者归为低危,该组短期不良事件率为2.7%。
- sFLHASc2低危且胸片阴性者事件率降至0.87%,阴性预测值99.1%(95%CI 96.5-100%)。
- 原始FLHASc区分度中等(AUC 0.71,95%CI 0.65-0.76)且校准欠佳,不如新模型FLHASc2。
- FLHASc2验证队列AUC 0.81(95%CI 0.73-0.88),推导队列AUC 0.79(95%CI 0.73-0.87),Brier评分均<0.10。
- 作者认为sFLHASc2联合胸片可能使近半数咯血病例安全离院,但需前瞻性管理试验确认其临床影响。
适用人群与场景
- 9家意大利急诊科连续就诊的成人咯血患者,共546例(POPEIHE研究,NCT06067997)。
诊断标准与关键阈值
- 简化FLHASc2(sFLHASc2)每个变量计1分,用于识别低危患者。
- sFLHASc2低危定义为评分对应的低危组,该组占47.8%,短期不良事件率2.7%。
- sFLHASc2低危联合胸片阴性者事件率0.87%,阴性预测值99.1%(95%CI 96.5-100%)。
研究设计与关键结果
- 研究类型为多中心前瞻性队列(POPEIHE,NCT06067997),纳入9家意大利急诊科546例连续成人咯血患者。
- 主要终点为院内死亡、需通气支持、ICU入住、输血或有创止血操作的复合终点。
- 原始FLHASc区分度中等(AUC 0.71,95%CI 0.65-0.76),校准欠佳。
- FLHASc2在随机推导队列(n=321)AUC 0.79(95%CI 0.73-0.87),在验证队列(n=225)AUC 0.81(95%CI 0.73-0.88),两队列Brier评分均<0.10。
- 简化版sFLHASc2每变量计1分,准确度与FLHASc2相当(AUC 0.80,95%CI 0.72-0.87)。
- sFLHASc2识别47.8%患者为低危,该组事件率2.7%;联合胸片阴性时事件率降至0.87%,阴性预测值99.1%(95%CI 96.5-100%)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究(POPEIHE,NCT06067997)。
- 作者结论:FLHASc2及其简化版是识别咯血患者短期不良结局低危的准确预后工具;sFLHASc2联合胸片可能使近半数病例安全离院。
- 局限:作者指出需前瞻性管理试验确认其临床影响。
对床旁实践的改变
- 作者认为sFLHASc2联合胸片可用于识别低危咯血患者,可能使近半数病例安全离院,但该做法尚需前瞻性管理试验确认。
- 原始FLHASc区分度中等且校准欠佳,床旁使用新模型FLHASc2或简化版sFLHASc2可能更准确。
指南或共识出处
- POPEIHE研究(NCT06067997),发表于Am J Emerg Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hemoptysis is a potentially life-threatening symptom that often prompts emergency department (ED) evaluation and hospitalization. Reliable prognostic tools to guide clinical decision-making and optimize resource use are currently lacking.
OBJECTIVE: To prospectively validate the Florence Hemoptysis Assessment Score (FLHASc) in patients presenting with hemoptysis to the ED, and to eventually derive and validate an improved version of the score (FLHASc2).
METHODS: We analyzed data from the POPEIHE study (NCT06067997), a multicenter prospective cohort of 546 consecutive adult patients presenting with hemoptysis to 9 Italian EDs. The primary outcome was a composite of in-hospital death, need for ventilatory support, intensive care unit (ICU) admission, blood transfusion, or invasive hemostatic procedures. We evaluated the prognostic performance of the original FLHASc, then derived a new model (FLHASc2) using multivariate logistic regression in a randomly selected derivation cohort (n = 321) and validated it in the remaining cohort (n = 225). A simplified version of the score was also tested.
RESULTS: The original FLHASc demonstrated moderate discriminatory ability (AUC 0.71; 95% CI: 0.65-0.76) and suboptimal calibration. The FLHASc2 showed improved performance (AUC 0.79, 95% CI: 0.73-0.87 in derivation and 0.81, 95% CI: 0.73-0.88, in validation cohorts; Brier score < 0.10 in both). The simplified FLHASc2 (sFLHASc2), assigning one point per variable, maintained comparable accuracy (AUC 0.80, 95% CI: 0.72-0.87) and identified 47.8% of patients as low risk (2.7% event rate). When combined with a negative chest X-ray, the observed event rate in this subgroup dropped to 0.87%, with a negative predictive value of 99.1% (CI 95%, 96.5-100%).
CONCLUSIONS: The FLHASc2 and its simplified version are accurate prognostic tools for identifying hemoptysis patients at low risk of short-term adverse outcomes. Use of the sFLHASc2 combined with chest X-ray may allow safe ED discharge in nearly half of cases. A prospective management trial is warranted to confirm its clinical impact.
TRIAL REGISTRATION NUMBER: NCT06067997.
参考来源
- Pelagatti L, Bartalucci P, Fabiani G, et al. Validation and implementation of the FLHASc score for risk stratification of patients with hemoptysis in the emergency department. Am J Emerg Med. 2026. PMID: 41905245. doi:10.1016/j.ajem.2026.03.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。